All In Biotech

Drug Trial Radar · NCT05867420

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

594

Planned (sponsor's estimate)

Start

Aug 2, 2023

Primary completion

Dec 31, 2026

Study completion Jun 30, 2028

Sponsor

Lead sponsor
AskGene Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
First posted
May 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • ASKG915Biological

    ASKG915 is administered intravenously at a scheduled dose. The drug was given once every 3 weeks or 4 weeks for a cycle.

  • Paclitaxel + BevacizumabDrug

    Paclitaxel is administered intravenously at a dose of 80 mg/m², once weekly on a 21-day cycle. Bevacizumab is administered intravenously at dose of 15mg/kg, once every 3 weeks on a 21-day cycle.

  • FruquintinibDrug

    The recommended dose of Fruquintinib is 5 mg orally once daily, with or without food for the first 21 days of each 28-day cycle.

  • DocetaxelDrug

    Docetaxel is administered intravenously at 75 mg/m², once every 3 weeks on a 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs)Time frame: 21days or 28 days
  2. Adverse events(AEs)Time frame: From the first dose to 30 days after the last dose

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.